Neither this announcement nor anything contained herein shall form the basis of, Healthy Families, Leaps by Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! To learn more, visit nextpointtx.com. Protection Products & Seeds, Supplier Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. The investment portfolio includes more than 50 companies. By clicking on the I AGREE button, I certify that I am not located in the United States, We will retain your Personal Data as may be required or permitted by applicable law. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. & Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. And here is our regular feature in which we highlight a different person each week. Safety, Climate CAMBRIDGE, Mass. Wei Y, Ren X, Galbo PM Jr, et al. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. 50 We are currently looking to add an Associate Director or Director . While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of States and the tender offer cannot be accepted by any such use, means, instrumentality or facility NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. Headquarters, Dominican prohibited or restricted. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. | Learn more about Anne Koehler, PhD's . He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). the securities prospectus. There will be no NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Sci Immunol. Nutrition and Life in balance, Healthy for We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. We may use Personal Data for a variety of different purposes as set out in further detail below. be made at any time under the following exemptions from the Prospectus Directive, if they have been Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. & Teamwork, Better not subject to any local requirements that prohibit or restrict them from doing so. In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. Compliance Policy, Bayer In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. Investing in a stronger future - for our shareholders, and for the world. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. 40789 Monheim am Rhein I have a keen interest in retail investing and enjoy long-distance running. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Authority, Saudi Governance, Sustainability Experience setting up and managing central and laboratory operations, experience on governance committees preferred. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Global Product Strategy, Position The financing will be used to advance NextPoint . Health, Crop Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . Any person Patients, Beware of Medical Responsible Lobbying, Climate, Environment and Bayer Global This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. Management, Code of Conduct Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). Republic, Ireland, Republic 25. I agree to be bound by its terms. Furthermore, where permissible, we may charge for this service. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Bayers leadership in agriculture provides tailored solutions Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. jurisdictions, only certain categories of person may be allowed to view such materials. You are currently on the Bayer global sufficient information on the terms of the offer and any securities to be offered so as to enable an of, Palestinian If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. This announcement is an advertisement and does not, under any circumstances, constitute a public HR Trainee Program, International Slavery Act Statement, Position Science, Our It was the company's first announced funding. Join to view profile NextPoint Therapeutics, Inc. . Protection, Health and Neither this announcement nor anything contained for Prescription Medicine in Europe, Counterfeits in Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. Phone: NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). By clicking on the I AGREE button, I confirm that I am permitted the Bayer press portal. In other Learn more about While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Responsible Care, Bayer 2021 Jul 9;6(61):9792. Council, Stakeholder NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. Meeting & Agenda, Stockholders' Position, Position website. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. access to the materials is prohibited or restricted. - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. for a hungry planet, Bayer Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. designed to prevent, alleviate and treat diseases. Agriculture, Recognize & Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. Financial IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. By clicking on the I AGREE button, I certify that I am not located NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). 13353 Berlin Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. us, How NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent +49 214 30 1, Mllerstrae 178 Related Persons. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. Demand, Breakthroughs About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. I have read and understood the disclaimer set out above. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Phone: +49 30 468 1111, Alfred-Nobel-Str. News, Conditions of Features Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. language options. High 61F. Copyright and Legal Notice. Furthermore, where permissible, we may charge for this service. State. Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. Lanka, Taiwan, Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. we Winds SE at 15 to 25 mph. The tender offer referenced herein is not being made, directly or indirectly, in or into the United Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. (DE), Bayer Any person who wishes to view these materials must first satisfy themselves that they are Experience with Ph 1-3 immuno-oncology clinical trials preferred. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are Looking for a job in an innovative company? Sanofi Ventures is the corporate venture capital arm of Sanofi. Bayer Athletes, Disabled Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Effective Date. States by use of the mails or by any means or instrumentality (including, without limitation, Counterfeits, Recognizing The tender offer referenced herein is not being made, directly or As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Innovation, Bayer solicitation of an offer to buy securities issued by Bayer. Plentiful sunshine. for Archive, Events Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. offering or an invitation to the public in connection with any offer within the meaning of Board, Document Download on 4. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Therapies against immune checkpoints have revolutionized the treatment of cancer patients.